HOME > TOP STORIES

TOP STORIES

ORGANIZATION Exclude 50 Yen or Lower Price Generics from “Off-Year” Re-Pricing: JGA Chief

January 15, 2018
REGULATORY Streamlining Regulations of Pharmaceutical Affairs to Be “a Top Priority” in 2018: MHLW Pharma Bureau Chief

January 12, 2018
BUSINESS Will Symbicort and Adoair Face Generic Entries This Year? Trade Group Has Seen High Hurdle for Inhaler Drugs

January 11, 2018
REGULATORY Balancing Innovation and Universal Coverage Was Key in Drug Pricing Reform: Health Minister

January 10, 2018
REGULATORY PMDA Chief Says Next Challenge Is to Boost Review Quality, Global Expansion Drive

January 9, 2018
BUSINESS Will Pricing Reform Spur Divestment of Off-Patent Brands in Japan? Next 3 Months Hold Key for Future Directions

January 1, 2018
BUSINESS Sawai Shooting for 12.7% Annual Growth for Upsher-Smith: Exec

December 27, 2017
BUSINESS MHLW to Use Its Classification Table to Pick PMP-Eligible Similar Drugs; How Will 3 Year 3rd Product Rule Affect I/O and Other Meds?

December 26, 2017
REGULATORY “Comprehensive Strategy” Updated after 2 Years, MHLW to Mull Procedures for Info Handover for Brand-Name Meds Bowing Out of Market

December 25, 2017
ORGANIZATION JPMA to Call for Improvements in PMP-Eligibility Criteria, Company Requirements: Chief

December 22, 2017
REGULATORY Chuikyo OKs Drug Pricing Reform Package; 30% Cap Set for “Category I” Companies Allowed to Maintain Full Prices

December 21, 2017
BUSINESS GSK Japan Pres. Kikuchi to Quit after Only 9 Months in Office

December 20, 2017
BUSINESS Gilead Aiming to Develop World’s First NASH Treatment, Hoping for Approval in 2020

December 20, 2017
REGULATORY (Update) Japan to Shave 720 Billion Yen through FY2018 Drug Price Revision

December 19, 2017
REGULATORY Govt to Draw Up “Plan to Strengthen Drug Discovery,” Boosting Budgets to Improve R&D Environment

December 18, 2017
BUSINESS Partnerships Hold Key to Success, Acquisition Not Our Goal: Takeda R&D Head

December 15, 2017
REGULATORY Chuikyo Debate Intermitted as Members Fume at Political Arrangement, New PMP Plan Still Clears Panel with Strings Attached

December 14, 2017
REGULATORY Chuikyo Members Snub Possible Change to 14-Day Prescription Limit

December 13, 2017
BUSINESS Japan Drug Makers Driven by Overseas Sales, See Tepid Revenue at Home: Jiho Tally

December 12, 2017
REGULATORY MHLW Proposes Physician Fee for Proper Antibiotic Use in Children, Aims to Cut Unnecessary Use: Chuikyo

December 11, 2017

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…